We next profiled the protein levels in prostate tumors by Western blot using the same panel from the monotherapy experiments to confirm the molecular activity of GSK690693 and characterize the expression patterns in response to AR with apalutamide and AKT inhibition alone or as a combination therapy in a subset of mice from Figure 7A,B (Figure 7A). This evidence concerns the gene AKT1 and prostate neoplasm.